Cannabinoids are a class of compounds found within humans, animals and plants. Endocannabinoids are cannabinoids usually found within something such as an animal or a human but cannabinoids found within plants are known as phytocannabinoids. This is where you will find the ever popular CBD (cannabidiol) and THC (Tetrahydrocannabinol) cannabinoids from the cannabis plant and there many potential medical and recreational benefits.
Both cannabinoids from within (endo) and from plants communicate with receptors in our endocannabinoid systems which are responsible for regulating our bodies, vital organs and nervous system. It is this potential control or influence of the regulatory process which could provide treatment for various pains and conditions. This article and attached paper will detail how the cannabinoid receptor 2 can be triggered by an agonist to treat different types of chronic pain and their related side effects.
Here is the full scientific article if you wish to download it.
The endocannabinoid system holds the cannabinoid receptors, CB1 and CB2, and the endogenous ligands anandamide (AEA, arachidonoylethanolamide) and 2-arachidonoylglycerol (2-AG). The use of cannabis has been detailed in the past and in recent papers for the treatment of pain, but the possibility for psychotropic impacts as a result of the triggering of central CB1 receptors places a halt upon its use. There are, however, a lot of modern techniques being undertaken to prevent this issue, and this paper represents a concise abstract of these techniques, with a particular mark upon CB2 receptor agonists.
Particular CB2 agonists are being produced for the medical treatment of inflammatory and neuropathic pain, as they show effectiveness in a range of pain models. CB2 receptors were originally detailed as being limited to cells of immune origin, but there is proof for their expression in human primary sensory neurons, and greater levels of CB2 receptors reported in human peripheral nerves have been displayed after injury, particularly in painful neuromas. CB2 receptor agonists produce antinociceptive impacts in models of inflammatory and nociceptive pain, and in some cases these impacts involve triggering of the opioid system.
These techniques might produce novel therapeutics that do not give off any of the psychotropic effects that prevent the medicinal use of marijuana.
CBD Lacks the Psychotropic Effects of Cannabis
The aim of this paper has been to indicate different techniques whereby the endocannabinoid system can be used to develop novel therapeutic drugs that don’t hold any of the psychotropic effects that place a limit upon the usefulness of THC. Lead findings and lead optimization activities at a number of industrial and academic pharmacology/chemistry laboratories has led to the discovery of numerous novel, particular and peripherally restricted alterers of the endocannabinoid system highlighted here.